PCOS and Irregular Periods: When to Act and What to Track First

Quick Answer: Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women of reproductive age, affecting roughly 1 in 8 women globally (Acta Obstetricia et Gynecologica Scandinavica, 2024). The 2023 International Evidence-Based Guideline defines an irregular cycle, the most common PCOS sign, as fewer than 21 days or more than 35 days between periods, measured more than 3 years after the first period (Journal of Clinical Endocrinology and Metabolism, 2023). When irregular cycles and clinical or biochemical hyperandrogenism, meaning acne, excess hair growth, scalp hair loss, or raised androgen blood markers, are both present, diagnosis is simplified and ultrasound or AMH testing is not required (Journal of Clinical Endocrinology and Metabolism, 2023). Track first: cycle length and regularity, ovulation signs, hirsutism, acne, and weight changes, with at least 3 months of cycle data as the baseline for a gynaecology consultation.

TL;DR

• PCOS affects roughly 1 in 8 women globally. In India, the most rigorous national study to date found a prevalence of 7.2% by NIH criteria and 19.6% by Rotterdam criteria (Acta Obstetricia et Gynecologica Scandinavica, 2024; JAMA Network Open, 2024).

• Irregular means fewer than 21 or more than 35 days between periods, more than 3 years after the first period (Journal of Clinical Endocrinology and Metabolism, 2023).

• 2023 diagnostic rule: PCOS is diagnosed when 2 of 3 criteria are met, namely irregular cycles, hyperandrogenism, and polycystic ovaries on ultrasound or a raised AMH level, after other causes are excluded (Journal of Clinical Endocrinology and Metabolism, 2023).

• Track first: cycle dates, flow, acne, facial or body hair, scalp hair loss, weight changes, and fasting glucose if available.

• When to act: cycles outside 21 to 35 days for 3 or more consecutive months, missed periods, new acne or hirsutism, or trying to conceive without success (American Society for Reproductive Medicine, 2023).

• First-line management: lifestyle modification across diet, activity and sleep, with combined oral contraceptive pills for cycle and hyperandrogenism control and metformin for metabolic features (American Society for Reproductive Medicine, 2023).

What Is PCOS?

PCOS is a metabolic and reproductive endocrine disorder defined by three features: ovulatory dysfunction, raised androgen hormones, and often polycystic ovarian morphology on ultrasound (Journal of Clinical Endocrinology and Metabolism, 2023). It is the most common endocrine disorder in women of reproductive age, with a global prevalence of 10% to 13%, or roughly 1 in 8 women (Acta Obstetricia et Gynecologica Scandinavica, 2024). Its reach goes well beyond periods and fertility. PCOS is also linked to insulin resistance, higher cardiovascular risk, sleep apnoea, mood disorders, and endometrial cancer (Acta Obstetricia et Gynecologica Scandinavica, 2024).

In India, the burden is significant and was measured directly by a 2024 national study. Ganie and colleagues, publishing in JAMA Network Open, surveyed 9,824 women aged 18 to 40 across India and found a weighted national PCOS prevalence of 7.2% by NIH 1990 criteria and 19.6% by Rotterdam 2003 criteria, with phenotype C the most common at 40.8% (JAMA Network Open, 2024). Among the Indian women diagnosed with PCOS in that study, 43.2% had obesity, 91.9% had dyslipidemia, 32.9% had non-alcoholic fatty liver disease, and 24.9% had metabolic syndrome, which shows how closely PCOS travels with metabolic disease (JAMA Network Open, 2024).

What Counts as an Irregular Period?

A normal menstrual cycle runs 21 to 35 days. Anything outside that window, measured more than 3 years after your first period, counts as ovulatory dysfunction under the 2023 International Evidence-Based Guideline: cycles shorter than 21 days, or longer than 35 (Journal of Clinical Endocrinology and Metabolism, 2023). Cycles between 36 and 90 days are oligomenorrhoea, meaning infrequent periods. Cycles past 90 days, or no period at all, are amenorrhoea.

Both patterns warrant a gynaecology visit, because chronic ovulatory dysfunction raises endometrial cancer risk through prolonged unopposed estrogen exposure (Acta Obstetricia et Gynecologica Scandinavica, 2024). In the 2024 Indian national study, fewer than 8 menstrual cycles a year was used as the working threshold for infrequent menstruation (JAMA Network Open, 2024).

How Is PCOS Diagnosed? The 2023 Rule, Simplified

PCOS is diagnosed when 2 of 3 criteria are met, after other causes have been excluded. The 2023 International Evidence-Based Guideline kept the 2003 Rotterdam framework with one important update: anti-Mullerian hormone (AMH) testing can now substitute for ultrasound in adults (Journal of Clinical Endocrinology and Metabolism, 2023).

In adult women, the three criteria are:

• Ovulatory dysfunction. Irregular cycles shorter than 21 or longer than 35 days, or absent periods.

• Clinical or biochemical hyperandrogenism. Visible signs such as hirsutism, acne or scalp hair loss, or raised androgens on a blood test.

• Polycystic ovarian morphology. 20 or more follicles per ovary on a high-resolution ultrasound, or an ovarian volume above 10 mL, or a raised AMH level.

When irregular cycles and hyperandrogenism are both present, the diagnosis is simplified and neither ultrasound nor AMH is needed (Journal of Clinical Endocrinology and Metabolism, 2023). For adolescent girls, both ovulatory dysfunction and hyperandrogenism must be present, and pelvic ultrasound is not recommended for diagnosis until 8 years after the first period (Journal of Clinical Endocrinology and Metabolism, 2023).

What Should You Track Before Seeing a Doctor?

Before your first gynaecology appointment, build at least 3 months of data across the dimensions below. That is the minimum a doctor needs to read a pattern rather than a single odd month.

• Cycle dates. Day 1, the first day of bleeding, of each cycle, the length of each cycle, and the length of bleeding.

• Flow. Light, moderate or heavy, with the number of pads or cups changed per day on the heaviest days.

• Ovulation signs. Mid-cycle cervical mucus changes, basal body temperature if you measure it, and mid-cycle pain.

• Skin and hair. Onset and spread of new acne, new or increased dark hair on the face, chest, abdomen or inner thighs, and any visible scalp hair loss or thinning.

• Weight. Current weight, recent changes, and waist circumference if you can measure it.

• Family history. PCOS, type 2 diabetes, infertility or early menopause in your mother, sisters or maternal aunts.

A simple cycle-tracking app makes this easier. Mylo's free in-app Period Calendar and Ovulation Tracker log cycle dates and ovulation windows automatically, which gives you a clean 3-month record to bring to your consultation.

When Should You See a Gynaecologist for Irregular Periods?

Book a gynaecology consultation if any of the following apply to you:

• Cycles consistently shorter than 21 or longer than 35 days for 3 or more consecutive months (Acta Obstetricia et Gynecologica Scandinavica, 2024).

• Skipped periods for 90 or more days with a negative pregnancy test.

• New or worsening acne, hirsutism or scalp hair loss alongside cycle changes (Acta Obstetricia et Gynecologica Scandinavica, 2024).

• Unexplained weight gain alongside cycle changes, particularly around the waist and abdomen.

• Trying to conceive for 12 months or more without success, or 6 months if you are over 35 (American Society for Reproductive Medicine, 2023).

How Is PCOS Managed Once Diagnosed?

PCOS cannot be cured, but it is highly manageable, and the 2023 guideline places lifestyle modification at the foundation of care. Diet, physical activity, sleep and behaviour change come first, and no single diet or exercise regimen has been shown to beat the others (American Society for Reproductive Medicine, 2023).

For pharmacological treatment, the 2023 guideline recommends combined oral contraceptive pills as first-line for menstrual irregularity and hyperandrogenism, and metformin primarily for metabolic features such as insulin resistance and weight (American Society for Reproductive Medicine, 2023). The main options compare as follows:

Myo-inositol is a supplement many women with PCOS consider, and the Mylo Care Ovaluna Tablets are formulated for this use. Myo-inositol is a second messenger in the insulin signalling pathway, and supplementing it is intended to support insulin sensitivity and, through that, ovarian function. Individual studies are encouraging: a 2024 prospective study of 90 Indian women with PCOS found that 68% restored regular menstrual cycles after 6 months on myo-inositol, alongside a significant fall in luteinising hormone and the LH to FSH ratio (Cureus, 2024). The honest caveat is that the systematic review which informed the 2023 guideline pooled 30 trials and concluded the overall evidence for inositol in PCOS is limited and inconclusive, while confirming that myo-inositol causes fewer gastrointestinal side effects than metformin (Journal of Clinical Endocrinology and Metabolism, 2024). Myo-inositol is therefore best seen as a reasonable option, particularly for women who cannot tolerate metformin, rather than a guideline-endorsed first-line treatment. Discuss any supplement with your gynaecologist before starting it.

Frequently Asked Questions

What counts as an irregular period? An irregular period means cycles shorter than 21 days or longer than 35 days between bleeds, measured more than 3 years after your first period. This is the definition in the 2023 International Evidence-Based Guideline (Journal of Clinical Endocrinology and Metabolism, 2023). Fewer than 8 cycles in a year, known as oligomenorrhoea, or no period for 90 or more days, known as amenorrhoea, are also clinically significant and warrant evaluation (Acta Obstetricia et Gynecologica Scandinavica, 2024).

Do I need an ultrasound to be diagnosed with PCOS? Not necessarily. If you have both irregular cycles and clinical hyperandrogenism, such as acne, hirsutism or scalp hair loss, that combination alone is enough to diagnose PCOS. Under the 2023 guideline, an ultrasound is not required when those two features are both present, after other causes are excluded. Anti-Mullerian hormone (AMH) testing can also now substitute for ultrasound in adults (Journal of Clinical Endocrinology and Metabolism, 2023).

Does myo-inositol actually work for PCOS? The evidence is mixed: individual studies show benefit, but the systematic review informing the 2023 guideline rated the overall evidence as limited and inconclusive. A 2024 prospective study of 90 Indian women found 68% restored regular menstrual cycles after 6 months of myo-inositol, with a significant fall in the LH to FSH ratio (Cureus, 2024). However, the 2024 systematic review that pooled 30 trials concluded the overall evidence for inositol in PCOS is limited and inconclusive, while confirming it causes fewer gastrointestinal side effects than metformin (Journal of Clinical Endocrinology and Metabolism, 2024). It is a reasonable option to discuss with your doctor, not a proven first-line treatment.

Can PCOS be cured? No. PCOS cannot be cured, but it is highly manageable. Lifestyle modification across diet, activity and sleep, pharmacological treatment with combined oral contraceptive pills or metformin, and consistent symptom tracking allow most women to control cycle regularity, fertility outcomes and metabolic risk (American Society for Reproductive Medicine, 2023).

Is PCOS the same as PCOD? They are used to mean the same condition, but PCOS is the precise clinical term. PCOD, polycystic ovarian disease, is an older term still common in India. The 2023 international guideline uses polycystic ovary syndrome, because the diagnosis is a syndrome of endocrine and metabolic dysfunction, not simply the presence of ovarian cysts (Journal of Clinical Endocrinology and Metabolism, 2023).

Sources

1. Teede H., et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2023; 108(10), 2447 — https://academic.oup.com/jcem/article/108/10/2447/7242360

2. Forslund M., et al. International evidence-based guideline on assessment and management of PCOS, a Nordic perspective. Acta Obstetricia et Gynecologica Scandinavica, 2024; 103(1), 7 — https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.14725

3. American Society for Reproductive Medicine. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, practice guidance, 2023 — https://www.asrm.org/practice-guidance/practice-committee-documents/recommendations-from-the-2023-international-evidence-based-guideline-for-the-assessment-and-management-of-polycystic-ovary-syndrome/

4. Ganie M.A., Chowdhury S., Malhotra N., et al. Prevalence, Phenotypes, and Comorbidities of Polycystic Ovary Syndrome Among Indian Women. JAMA Network Open, 2024; 7(10), e2440583 — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825233

5. Fitz V., Graca S., Mahalingaiah S., et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. Journal of Clinical Endocrinology and Metabolism, 2024; 109(6), 1630 — https://academic.oup.com/jcem/article/109/6/1630/7504796

6. Minthami Sharon P., Mellonie P., Manivannan A., Thangaraj P., Logeswari B.M. The Effectiveness of Myo-Inositol in Women With Polycystic Ovary Syndrome: A Prospective Clinical Study. Cureus, 2024; 16(2), e53951 — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10926319/

7. Mylo, Ovaluna for PCOS and PCOD, Mylo Care product page, 2026 — https://mylofamily.com/product/ovaluna-conception-fertility-supplements-for-women-prenatal-vitamins-promote-natural-conception-impr-3408